XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Narrative (Details)
shares in Millions
 3 Months Ended
Aug. 29, 2023
USD ($)
shares
Sep. 30, 2023
USD ($)
shares
Sep. 25, 2023
USD ($)
Apr. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Feb. 28, 2023
Dec. 31, 2022
USD ($)
XCOM Labs, Inc.              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business combination, equity interest issued (in shares) | shares 60.6            
Business combination, equity interest issued, amount $ 70,400,000            
XCOM Labs, Inc. | Common Stock              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business combination, equity interest issued (in shares) | shares 41.8            
Equity issued in business combination, fair value $ 51,400,000            
Business combination, equity interest issued, amount $ 51,400,000            
XCOM Labs, Inc. | Common Stock, Restricted              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business combination, equity interest issued (in shares) | shares 18.8            
Equity issued in business combination, fair value $ 19,000,000            
Business combination, equity interest issued, amount $ 19,000,000            
Restricted Stock Units (RSUs)              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Unites granted (in shares) | shares   44.5          
Performance period   4 years          
Fair value of award     $ 39,500,000        
Underlying Stock Price and Exercise Price (in dollars per share) | XCOM Labs, Inc. | Common Stock              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair Value of Consideration 1.23            
Underlying Stock Price and Exercise Price (in dollars per share) | XCOM Labs, Inc. | Common Stock, Restricted              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair Value of Consideration 1.13            
2023 Funding Agreement              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Debt instrument, fair value       $ 76,000,000      
2023 Funding Agreement, Thermo Guarantee              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Debt instrument, fair value       $ 6,900,000      
2021 Funding Agreement              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Debt instrument, fair value   $ 76,300,000          
2023 Funding Agreement | Level 3              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Embedded derivative liability   $ 100,000          
2023 Funding Agreement | Discount rate              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Derivative liability, measurement input   0.0873   0.0852   0.0852  
2019 Facility Agreement              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Embedded derivative liability         $ 0    
2019 Facility Agreement | Level 3              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Embedded derivative liability             $ 100,000
2023 Funding Agreement, Thermo Guarantee | Discount rate              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Derivative liability, measurement input       0.0622      
2021 Funding Agreement | Discount rate              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Derivative liability, measurement input   0.0852